Target personalized drug-cost savings with precision

Pharmacy-to-provider outreach delivers actionable, member-specific, measurable savings without impacting member cost share or rebates.

Continuous, member-level data oversight that reveals savings opportunities

HighTouchRx^® continuously monitors members’ drug regimens from day 1 to uncover potential cost saving therapy recommendations. Equipped with actionable insights, HighTouchRx pharmacists can effectively collaborate with members, pharmacies and prescribers to help drive appropriate therapy changes while maintaining member cost share and rebates.

Therapy optimization

A paragraph is a self-contained unit of a discourse in writing dealing with a particular point or idea. Paragraphs are usually an expected part of formal writing, used to organize longer prose.

Specialized outreach

Coordinate with pharmacists to provide high-touch outreach to prescribers and pharmacies.

Maximized value

Gain real savings while retaining member cost share and rebates.

$250M+

Since its launch, HighTouchRx has saved commercial and Medicare plans $200M+.¹

2,500+

HighTouchRx uses thousands of clinical drug regimen rules — updated continuously with AI and market surveillance — to identify nonoptimized drug use.

3:1

Clients realize a 3:1 return on investment (ROI) one year after program implementation.²

50

HighTouchRx has achieved a Net Promoter Score (NPS) of 50.³

Real-word savings

SAVINGS PER CASE

$194,300

ROI

5:1

Exceeding guarantees

An employer group with 7,000 lives implemented HighTouchRx. They saw savings of $194,300, with HighTouchRx providing an ROI of 5:1.⁴

SAVINGS PER CASE

$11,500

Eliminating duplicate therapies

HighTouchRx identified a member who had been using both Mounjaro and Ozempic for two months. A pharmacist reached out to the provider, who switched the member to a single glucagon-like peptide-1 (GLP-1) receptor agonist medication, resulting in $11,500 in savings and reducing the likelihood of adverse effects.³

Award-winning research & support

Cystic fibrosis oversupply

HighTouchRx received the Silver Award at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023. When high-cost cystic fibrosis drugs were oversupplied, HighTouchRx pharmacists intervened to extend time between refills, generating an average savings of $30,732 per case.

See the research

Multiple sclerosis (MS) brand-to-generic switches

HighTouchRx was a Gold Award recipient at the AMCP Annual Meeting 2024, recognized for delivering an average savings of $73,142 per case for recommending conversions from high-cost brand-name MS drugs to lower-cost generics.

View the findings

Savings methodology validation

The Academy of Managed Care Pharmacy (AMCP) awarded our HighTouchRx platinum for its significant impact in identifying and managing duplicate incretin therapies, demonstrating $3.5 million in validated savings and achieving a 66% success rate in transitioning patients to single-drug therapy.

Check out the study

Cost containment

HighTouchRx received a Platinum AMCP award in 2023 for its significant impact in identifying and managing duplicate incretin therapies (e.g., GLP-1s, dipeptidyl peptidase IVs [DPP-IVs]), demonstrating $7,578 in savings per case.

Check out the research

Footnotes

Savings and ROI numbers shown are best results that do not guarantee future results.
All brand names are property of their respective owners.

¹Prime Therapeutics internal data, 2025
²Rebates and member cost share held whole.
³HighTouchRx client satisfaction survey 2025
⁴Case studies based on 2024 actual results; past results do not guarantee future results

Integrated data reveals savings opportunities

Finding and supporting members with complex conditions helps lower costs for health plans, employers and members. HighTouchRx^® applies exclusive clinical predictive modeling to your medical and pharmacy data, making it easy to quickly determine high-cost members and offer interventions. And the best part? HighTouchRx is available to all lines of business.